Navigation Links
Summer Street Research Announces Expansion of Research Team with the Addition of Ling Wang, CFA, Senior Biotechnology Analyst
Date:7/14/2011

BOSTON, July 14, 2011 /PRNewswire/ -- Summer Street Research Partners announced today that Ling Wang, CFA, has joined the firm as senior biotechnology analyst, director. She will be focused on covering the biotechnology sector, continuing to build out the biotechnology sector for the firm. Ms. Wang joins the firm with years of equity research experience.  

"We are very excited to welcome Ling to the research team at Summer Street. Ling is a proven analyst with extensive Wall Street experience," says Dr. Mark Landy, director of research for Summer Street Research. "We believe Ling will bring valuable insights and a unique perspective to our research product, which will benefit our clients."

Prior to joining Summer Street, Ms. Wang was a senior vice president and senior biotechnology analyst at Brean Murray, Carret & Co. since 2009. Prior to Brean Murray, she was a research associate covering biotechnology stocks at Rodman & Renshaw from 2006 to 2008. Prior to that, she was a research assistant in the life science group at Manning & Napier Advisors, Inc. (an investment firm with approximately $16 billion assets under management) from 2004 to 2006. Ms. Wang earned her undergraduate degree in biology from Beijing University. She also holds a master's degree in molecular pharmacology from Albert Einstein College of Medicine and an MBA degree in finance from Yale University.

"I'm very excited to join Summer Street," Ms. Wang says. "With their unique MCRI consulting network and their singular focus on the healthcare sector, I believe Summer Street is the right platform for me to add real value to institutional healthcare investors on important and timely topics."  

About Summer Street Research, Inc.

Summer Street Research Partners is an investment banking, institutional equity research and trading firm that focuses exclusively on the healthcare sector. Our mission is to help our clients maximize returns by providing the best healthcare research, ideas and investment opportunities. The firm was founded in 2002, with a culture of providing a proprietary equity research, utilizing more than 10,000 physicians and industry professionals provided through MCRI, a division of Summer Street Research Partners.  www.ssrp.com

Media Contact:
Cyrus Alphonse
617-532-6464


'/>"/>
SOURCE Summer Street Research Partners
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
2. Expanded Lipoprotein Testing, VAP® Cholesterol Test Discussed at National Lipid Association Summer Clinical Lipid Update
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Health Robotics and McKesson to Showcase i.v.STATION and i.v.SOFT at ASHPs Summer Meeting, Tampa, June 6-8, 2010
5. Summerhill Biomass Systems Unveils Solid Biomass Technology System at Syracuse Expo
6. ECBC Now Accepting Applications for 2009 Minority Undergraduate Summer Internship Program
7. LI-COR Updates Product and Application Guide for Summer 2008
8. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
9. Scott Garrett Joins Water Street Healthcare Partners
10. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
11. Aethlon Medical to Present at the Wall Street Analyst Forum 22nd Annual Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
(Date:12/7/2016)...  Genprex, Inc. a biopharmaceutical company focused on ... announced that it has retained ICR Healthcare, a ... and advisory firm, to develop and implement an ... investor relations, public relations and digital communications to ... Genprex and its lead candidate Oncoprex, which is ...
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
Breaking Biology Technology:
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):